Pharmaceutical Executive
Pediatric drugs require investments in formulation, but the market opportunity is worth the cost.
David Bergstrom
Advertisement
Articles by David Bergstrom
Advertisement
Latest Updated Articles
The Growing Pediatrics MarketAugust 1st 2004
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
5